Edwards Lifesciences Corporation Common Stock vs Vaxcyte Inc. Common Stock — how do they compare? Edwards Lifesciences Corporation Common Stock trades at $87.06 (market cap $49.15B), while Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B). The key difference: Edwards Lifesciences Corporation Common Stock is far larger — about 4.7× Vaxcyte Inc. Common Stock's market cap, and Vaxcyte Inc. Common Stock is trading nearer its 52-week high, Edwards Lifesciences Corporation Common Stock nearer its low. Which is the better fit depends on your goals.
| EW | PCVX | |
|---|---|---|
Market Cap | $49.15B | $10.51B |
Volume | 3,642,969 | 2,644,694 |
Sector | Health | Health |
52-Week High | $95.18 | $73.82 |
52-Week Low | $72.65 | $40.32 |
Enterprise Value | $45.60B | $9.14B |
Typical Hold Time | — | 0 Days |
Signals from Pluang's Aura AI — not financial advice
Edwards Lifesciences (EW) trades at $85.27, down 1.3% with bearish technical signals. The company maintains strong fundamentals with 77.84% gross margins and recent FDA approval for the AUTUS pediatric valve. Despite a high P/E of 50.76, analysts project 20% upside to the $102.44 consensus target. Recent earnings show mixed results with Q1 and Q2 beats but a Q4 miss.
EW faces valuation concerns with declining net income margins from 17.69% to 15.43% year-over-year. Technical resistance at $86-89 and negative cash flow trends present near-term challenges. However, institutional accumulation and zero sell ratings suggest long-term confidence in structural heart growth platforms.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Edwards Lifesciences develops medical technologies for structural heart disease. Its products include transcatheter aortic-valve replacement, mitral and tricuspid therapies, and surgical structural-heart technologies.
Read more on EW →Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →